Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. by Kranzer, Katharina et al.
Lawn, SD; Kranzer, K; Wood, R (2009) Antiretroviral Therapy for
Control of the HIV-associated Tuberculosis Epidemic in Resource-
Limited Settings. Clinics in chest medicine, 30 (4). 685-+. ISSN
0272-5231
Downloaded from: http://researchonline.lshtm.ac.uk/3288/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Antiretroviral Therapy for Control of the HIV-associated
Tuberculosis Epidemic in Resource-Limited Settings
Stephen D. Lawna,b,∗, Katharina Kranzera,b, and Robin Wooda
aThe Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of
Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South
Africa.
bDepartment of Infectious and Tropical Diseases, Clinical Research Unit, London School of Hygiene
and Tropical Medicine, London, UK.
Abstract
Great progress has been made over the past few years in HIV testing in patients who have tuberculosis
(TB) and in the scale-up of antiretroviral therapy. More than 3 million people in resource-limited
settings were estimated to have started antiretroviral therapy by the end of 2007 and 2 million of
these were in sub-Saharan Africa. However, little is known about what impact this massive public
health intervention will have on the HIV-associated TB epidemic or how antiretroviral therapy might
be used to best effect TB control. This article provides an in-depth review of these issues.
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HIV-associated tuberculosis epidemic
Tuberculosis (TB) remains a major challenge to global public health and has proved
particularly difficult to control in regions with high HIV prevalence. Of the estimated global
burden of 9.3 million new TB cases in 2007, 1.37 million (14.8%) were associated with
HIV. TB remains a major cause of mortality, with an estimated 1.3 million deaths among
individuals who are not infected with HIV and a further 0.5 million TB deaths among people
who have HIV. The latter accounted for almost 25% of global AIDS-related mortality.
HIV was a key factor underlying the approximately 1% annual increase in global TB incidence
rates between 1990 and 2004. Sub-Saharan Africa has borne the brunt of this co-epidemic,
accounting for 79% of cases of the global burden of HIV-associated TB in 2007. Here TB
notification rates have increased three- to fivefold in many countries, especially in the south
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of the continent where HIV prevalence is highest. As a result, TB incidence rates in the region
far exceed those observed in most other parts of the world (Fig. 1). Elsewhere, South and East
Asia account for 11% of the global burden of HIV-associated TB and the combined epidemics
of HIV and drug resistant TB are undermining TB control in Eastern Europe.
Millennium development goals for tuberculosis control
The Millennium Development Goals (MDG) TB control targets are to halt and start to reverse
the rising incidence of TB and to halve the 1990 prevalence and death rates by 2015. Although
the absolute number of TB cases occurring worldwide continued to increase in 2007, it was
largely the result of global population growth. Global TB incidence rates are actually thought
to have peaked in 2004 at 142 cases per 100,000 population and to have started to slowly
decrease thereafter.
This recent downward trend in global TB incidence was preceded by a sustained decrease in
global TB prevalence since 1990. Rates of TB mortality (HIV-associated and non-HIV–
associated) are also estimated to have peaked around the year 2000 and have since
decreased. Despite these encouraging overall trends, however, the global MDG TB control
target of halving the 1990 TB prevalence and death rates by 2015 will not be achieved with
current rates of progress. Targets are projected to be missed in the regions of sub-Saharan
Africa and Eastern Europe where the TB and HIV epidemics intersect. Concerted international
public health action is needed.
International public health response
Since the World Health Organization (WHO) declaration in 1993 that TB was a global
emergency, the directly observed treatment, short-course (DOTS) strategy has served as the
key public health intervention that has been widely implemented to effect global TB control.
This strategy prioritizes the detection of patients who are sputum smear-positive presenting to
health facilities with symptoms and aims to achieve high cure rates using short-course
rifampicin-containing chemotherapy. Although this has been effective in most parts of the
world, contributing to the sustained downward trend in global TB prevalence, it has
nevertheless been comparatively ineffective in countries with high HIV prevalence. Although
the DOTS strategy remains the foundation for TB control programs in high HIV-prevalence
settings, it is clear that additional interventions are needed.
Under the leadership of the WHO and the Stop-TB Partnership, TB-HIV guidelines, a TB-HIV
strategic framework, and an interim TB-HIV policy were published between 2002 to 2004 to
address the challenge of HIV-associated TB in severely affected countries. The aim of these
interventions is to reduce the burden of TB in people who are HIV-infected through use of TB
prevention strategies, such as isoniazid preventive therapy, intensified case finding, infection
control, and antiretroviral therapy (ART). A further aim is to reduce the impact of HIV in
patients who have TB through HIV testing and use of trimethoprim-sulfamethoxazole
prophylaxis and ART.
Great progress has been made over the past few years in HIV testing in patients who have
TB and in the scale-up of ART. More than 3 million people in resource-limited settings were
estimated to have started ART by the end of 2007 and 2 million of these were in sub-Saharan
Africa. However, little is known about what impact this massive public health intervention will
have on the HIV-associated TB epidemic or how ART might be used to best effect TB control.
This article provides an in-depth review of these issues.
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Tuberculosis incidence rates in antiretroviral treatment cohorts
Data from 12 observational studies that included over 32,000 participants living in high-income
countries (seven studies) and resource-limited countries (five studies) are shown in Table 1.
In two of these studies, TB rates were simply compared before and after 1995 when triple-drug
ART was introduced, whereas in the remaining studies TB rates were determined according
to person-time of exposure to ART. All but two of these studies found a statistically significant
reduction in TB risk during ART.
In nine studies, the reductions in TB risk associated with use of antiretrovirals are expressed
as hazard ratios adjusted for covariates, such as baseline patient characteristics and
antiretroviral regimen. Triple-drug ART was associated with a risk reduction of more than 70%
in the majority of these studies (n = 6) with a range of 54% to 92% (see Table 1). This protective
effect against TB was seen in countries with low-TB burden, such as the United States, and
South Africa, which has the highest burden of HIV-associated TB in the world. The benefits
of ART are seen across a broad range of degrees of baseline immunodeficiency and clinical
stage of disease, although the absolute reduction in TB rates is greatest in those with the most
advanced HIV disease (Fig. 2).
TB incidence rates in 14 ART cohorts are shown in Table 2. The observed rates are
heterogeneous and are likely to vary according to the local TB incidence rates, the baseline
degree of immunodeficiency, and the duration of ART. Several studies report rates stratified
according to duration of ART and these are shown in Fig. 3. The figure illustrates the major
differences between TB rates in various settings and the rapidity of the beneficial impact of
ART. All of these studies show time-dependent reductions in TB rates, with most of the benefit
occurring within the first 2 years of ART. Although reductions in TB incidence in high- and
low-TB burden settings are proportionately similar, the greatest absolute reductions in TB risk
of course occur in high-TB prevalence settings.
Baseline risk factors for incident TB during ART in resource-limited settings included low-
CD4 cell count, advanced WHO stage of disease, younger age, low socioeconomic status, past
history of TB, and male sex. In high-income countries, baseline risk factors for TB included
low-baseline CD4 count and HIV transmission category. However, the risk of TB decreased
as CD4 cell counts rose (Fig. 4). Thus, with increasing duration of treatment, the immunologic
response to ART, rather than baseline patients' characteristics, emerges as the dominant
predictor of TB risk. The strong relationship between TB rates and updated CD4 cell counts
during ART is shown in Fig. 5.
Data are scarce concerning TB rates among those with optimum immune recovery. However,
in a study in South Africa, subjects achieving CD4 cell counts of greater than 500 cells/μL
retained a TB rate that was approximately two-fold higher than that in subjects who were non-
HIV–infected living in the same community. These data suggest that recovery of TB-specific
immune function during ART may be incomplete even at high CD4 cell counts.
Antiretrovirals and tuberculosis incidence at a community level
Despite the extensive data that have arisen from observational cohort studies, empiric data
regarding the impact of ART on TB incidence rates at the community level are lacking. This
is a difficult issue to study. In-depth observational studies of sentinel communities with high
TB and HIV prevalence during scale-up of ART are needed. Outcome measures should include
the impact of ART scale-up on TB incidence and prevalence, TB transmission, and TB-
associated mortality. However, trends in TB incidence and mortality over time will inevitably
be confounded by other variables, such as the natural evolution of the HIV epidemic, changes
over time in socio-economic factors, and the efficiency of TB control programs. Ecological
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studies comparing settings differing in the rapidity and coverage of ART scale-up may provide
further insights.
Likely limited impact of antiretrovirals at community level
Despite the major beneficial impact of ART on TB rates in observational cohorts,
mathematical modeling studies suggest that the impact of ART on TB rates at a population
level will be limited. Various observations suggest that this conclusion is likely to be
true and are discussed in full in Box 1.
Risk of Tuberculosis Before Starting Antiretroviral Treatment
Following HIV seroconversion, risk of TB doubles and continues to increase as CD4 cell counts
decline. Patients, therefore, typically remain at a high risk of TB for many years before
eligibility for ART. Further compounding this, HIV infection is often only diagnosed once
patients present to medical services with advanced immunodeficiency and either have active
TB or high risk of developing TB in the short term.
In addition to TB occurring before enrollment for ART, a substantial burden of prevalent TB
may be diagnosed in ART services during screening before starting treatment. The proportion
detected may vary according to the intensity of investigation and availability of mycobacterial
culture. In two studies from South Africa, 20% to 25% of adults referred for ART who did not
already have a TB diagnosis were found to have sputum culture-positive TB, the majority of
which was smear-negative.
The overall cumulative risk of TB before initiating ART may therefore be very high. In one
ART service in Cape Town, this represented two thirds of adult patients. Thus, ART is
frequently implemented too late in the course of HIV progression to prevent much of the overall
burden of HIV-associated TB.
Incidence of Tuberculosis During Antiretroviral Therapy
In addition to TB occurring pre-ART, TB incidence rates during ART persist at rates
substantially higher than background (see Table 2). During the initial months of treatment, a
proportion of TB cases present as a result of the unmasking of subclinical TB during ART-
induced restoration of TB-specific immune responses. Through this mechanism, the risk of TB
during ART may actually increase in the short term after starting ART. However, the size of
this effect will be highly dependent on the efficiency with which patients are screened for
clinical and subclinical TB before commencing ART. Unmasking TB was estimated to account
for more than one third of the TB cases presenting during the first 4 months of ART in a
treatment service in South Africa.
In the longer term, TB rates during ART appear to be largely dependent on changes in the CD4
cell count over time. With CD4 cell counts less than 200 cells/μL, TB rates exceeded 9.0 cases/
100 person-years (PY) in the same study from South Africa. Rates at higher CD4 counts were
substantially lower, but nevertheless remained more than five-fold higher than rates in
individuals who were non-HIV-infected living in the same community.
Persistence of high TB rates in ART cohorts is likely to reflect the fact that most patients spend
prolonged periods at CD4 cell counts less than 500 cells/μL. In addition, immunologic studies
also suggest that defects in functional TB-specific immune responses may persist despite
ART, leaving patients vulnerable to TB long-term. This may be compounded by high rates of
nosocomial exposure to TB within overcrowded ART services where infection control
procedures are often lacking.
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Despite high early mortality risk, long-term survival after the first year of ART is likely to be
good in patients who are in treatment programs in sub-Saharan Africa. In light of the persistence
of high rates of TB during ART, the life-time cumulative risk of TB in survivors will inevitably
be high. It is not yet clear whether this is reduced compared with the cumulative life-time risk
in patients who are HIV-infected in the pre-ART era.
A further critical factor affecting the magnitude of the impact of ART on community TB rates
is the coverage of ART. In mathematical modeling studies, high coverage with ART was
needed to impact TB rates. However, coverage in sub-Saharan Africa was only approximately
one third of those estimated to be in need at the end of 2007. In most countries, rates of HIV-
testing are low and only a small proportion of individuals who are HIV-infected know their
HIV status.
The magnitude of any impact of ART on TB transmission is unknown. It has been generally
assumed that patients who are HIV-infected are not the key drivers of TB transmission in the
community in view of their comparatively low infectivity. If true then ART is unlikely to have
a major impact on community TB transmission. Conversely, however, patients receiving ART
survive longer and remain at substantial risk of TB that may be more likely to be sputum smear-
positive as immune function improves. However, transmission risk among such patients
remains undefined.
Perhaps the most important issue relating to TB transmission is that occurring between
individuals who are HIV-infected in health care settings. This issue was exemplified by the
outbreak of multidrug-resistant and extensively drug-resistant TB in a hospital-based ART
service in rural South Africa from 2005 to 2006. Although ART may serve as a potent
preventive therapy for TB, ART services without adequate infection-control measures may
nevertheless be sites associated with high risk of nosocomial TB transmission and outbreaks.
Enhancing the impact of antiretrovirals on tuberculosis control
Earlier Initiation of Antiretroviral Therapy
It is likely that ART could be used much more effectively as a TB-prevention strategy (Box
2). ART should be initiated much earlier in the course of disease than is currently being done.
In sub-Saharan Africa, the median CD4 cell count at baseline in ART programs is often in the
range of 100 to 150 cells/μL and many patients have already had TB before starting ART.
Earlier HIV diagnosis would permit more timely initiation of ART, thereby enhancing its role
as a preventive intervention. Consideration should be given to revision of ART eligibility
guidelines in countries, such as South Africa, where treatment is restricted to patients who have
WHO stage 4 disease or blood CD4 cell counts of less than 200 cells/μL. A randomized
controlled trial of early (CD4 200–350 cells/μL) versus late (CD4 <200 cells/μL) initiation of
ART in Haiti was discontinued in 2009 following interim analysis. In the delayed initiation
group, the mortality was fourfold higher and the TB incidence rate was twofold higher than
in the early initiation group, clearly demonstrating the benefits to be derived from earlier
treatment.
A mathematical modeling study explored the potential impact of a test and treat strategy
whereby all patients who are diagnosed with HIV are immediately offered ART irrespective
of the blood CD4 cell count. Although interest has primarily focused on the potential of such
a strategy for HIV prevention, this also has the potential to impact TB control. The rapidity of
scale-up of ART may also be an important variable that affects not only the numbers of deaths
averted by ART but also the number of TB cases averted.
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Adjunctive Interventions
Because TB rates do not decrease to background levels during long-term ART, use of
concurrent adjunctive interventions is needed. Three key interventions are encompassed within
the WHO 3I's strategy launched in April 2008. This three-pronged strategy includes intensified
case finding, isoniazid preventive therapy, and infection control.
Intensified case finding is needed in ART services as this designates patients as either having
active TB (and in need of treatment) or being TB-free and potentially benefitting from isoniazid
preventive therapy. Initiation of TB treatment in those who have disease also plays a critical
role in reducing the risk of nosocomial TB transmission. Observational data have examined
the potential role of isoniazid preventive therapy concurrently with ART in Brazil. Although
isoniazid alone was not associated with significant reductions in TB risk compared with the
nonintervention group, it was suggested that concurrent isoniazid preventive therapy during
ART provided an additive benefit. However, this requires confirmation by randomized
controlled trials.
Impact of antiretrovirals on mortality risk
TB case fatality rates (the proportion of patients dying while receiving antituberculosis
treatment) in Africa are 16% to 35% among patients who are infected with HIV and not
receiving ART and 4% to 9% among individuals who were not infected with HIV. The authors
identified observational studies (n = 8) that provided information on the impact of ART on
survival of patients who have HIV-associated TB (Table 3). Of these, half were from high-
income countries and half were from resource-limited settings.
One study using national data from The Netherlands found a 54% reduction in risk of death of
patients who had HIV-associated TB treated in the ART era compared with in the pre-ART
era. Of seven further studies, six found that use of ART was associated with significant
reductions in mortality risk of 64% to 95% in adjusted analyses (see Table 3). The remaining
study from Malawi found no such association but analyses were not adjusted for CD4 cell
counts and ART was not commenced during the intensive phase of TB treatment when most
deaths occurred.
A key issue that remains to be resolved regarding the clinical management of patients who
have HIV-associated TB is the optimal time to start ART during TB treatment. Early mortality
rates are extremely high among patients waiting to start ART in resource-limited settings.
However, early initiation of ART in those who have HIV-associated TB increases the risk of
TB immune reconstitution disease. This increase is associated with mortality risk in a small
proportion of patients but may be greater in those who have neurologic involvement. Overall,
the risk/benefit ratio is likely to favor initiation of ART in the initial weeks of TB treatment,
but the outcome of randomized controlled trials are awaited.
Antiretrovirals and tuberculosis treatment outcomes
Data concerning the impact of ART on TB treatment outcomes other than death are scarce. A
large retrospective observational cohort study in San Francisco reported that use of ART was
associated with significant shortening of the time to smear and culture conversion. A systematic
review of 32 studies and recently published data from Rio de Janeiro, South African gold mines,
and San Francisco confirm that patients who have HIV-associated TB are at increased risk of
recurrent disease, especially those who have low CD4 cell counts. Various strategies can be
used to address high recurrence rates, including prolongation of the duration of TB therapy
and use of secondary isoniazid prophylaxis. However, more recent data from a study in Brazil
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have now shown that recurrence rates were halved in patients who had TB who received
ART. It remains to be determined whether combining ART and isoniazid has an additive effect.
Summary
The HIV-associated TB epidemic is undermining progress toward TB control and additional
interventions must be used in combination with the DOTS strategy in resource-limited settings.
Observational cohort studies in a wide range of settings have demonstrated that the use of ART
is associated with a 54% to 92% reduction in TB incidence rates and a halving of the risk of
TB recurrence. ART is also a potent means of improving the survival of those who have HIV-
associated TB, reducing mortality rates by 64% to 95%. Thus, ART confers huge benefits to
individual patients.
However, limited data are available concerning the effects of ART on TB rates at a population
level. Mathematical modeling and a range of empiric observations suggest that this may be
limited, largely because of the high burden of TB that occurs before ART initiation and the
persistence of TB rates several-fold higher than background rates during long-term ART. Thus,
ART is likely to have limited impact on lifetime cumulative risk of TB. To enhance the impact
on community TB control, it is likely that ART will need to be implemented with high-
population coverage and at much higher CD4 cell counts than is currently the case. Adjunctive
interventions, such as those included in the 3I's policy, may help reduce rates further.
Despite the likely limited impact on TB rates at a community level, ART nevertheless
transforms the prognosis of patients who have HIV-associated TB. By reducing mortality rates,
ongoing ART scale-up may accelerate progress toward the MDG TB control target of halving
the 1990 mortality rate by 2015.
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Fig. 1.
Estimated TB incidence rates by country for 2006. (Reproduced from World Health
Organization. Global Tuberculosis Control. Surveillance, planning, and financing. WHO/
HTM/TB/2008.393. Geneva (Switzerland): World Health Organization; 2008; with
permission.)
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Fig. 2.
TB incidence (cases per 100 person-years) among patients who were HIV-infected in Cape
Town, South Africa, who were or were not receiving antiretroviral therapy. Patients were
stratified according to baseline CD4 cell count and WHO stage of disease. Overall, TB rates
were approximately 80% lower among those receiving ART, which was observed across a
broad spectrum of baseline immunodeficiency. (Data from Badri M, Wilson D, Wood R. Effect
of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort
study. Lancet 2002;359(9323):2059–64).
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Fig. 3.
TB incidence rates during ART. The graph shows data from studies included in (see Table 2)
in which changing TB incidence rates were calculated according to increasing duration of ART.
The two lowest curves present data from studies conducted in high-income countries. The
remaining four studies are from South Africa (diamonds and inverted triangles), a range of
resource-limited countries (circles), and Uganda (squares).
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Fig. 4.
Decreasing TB incidence rates (cases/100 person-years, white squares) and rising median CD4
cell counts (cells/μL, black diamonds) during the first 3 years of ART. These data are from a
community-based ART cohort in a township in Cape Town, South Africa. (Data from Refs.).
Lawn et al. Page 14
Published as: Clin Chest Med. 2009 December ; 30(4): 685–699.
Sponsored D
ocum
ent 
 Sponsored D
ocum
ent 
 Sponsored D
ocum
ent
Fig. 5.
Relationship between updated CD4 cell-count measurements made every 4 months during 4.5
years of ART in a treatment cohort in a township in Cape Town, South Africa. Observed rates
are shown as diamonds together with 95% confidence intervals indicated by bars. A logarithmic
trend line is overlaid (R2 = 0.97). TB incidence rates are seen to fall substantially as CD4 cell
counts increase during ART. (Data from Lawn SD, Myer L, Edwards D, et al. Short-term and
long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy
in South Africa. AIDS 2009;23(13):1717–25.)
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Table 1
Studies (n = 12) reporting the impact of antiretroviral therapy on tuberculosis incidence rates in observational
cohorts
Study Setting N Study Period Study Design Impact of
ART on TB
Incidence
Rates
Adjusted
Hazards Ratio
(95%CI)
Studies comparing TB rates in cohorts before and after introduction of ART
Brodt et al, 1997 Germany 1003 1992–1996 Cohort of homosexual men 1992–
1996
No change in
overall cohort
incidence rates
(range, 2.1–
2.7 cases/100
PY)
–
Kirk et al, 2000 Europe 6,972 1994–1999 EuroSIDA multicenter cohort
1994–1999
Overall rate in
cohort
decreased
from 1.8 cases/
100 PY to 0.3
cases/100 PY
–
Studies comparing TB rates in patients receiving or not receiving ART
Ledergerber et al,
1999
Switzerland 2410 1995–1997 Swiss HIV Cohort Study Rate 0.78
cases/100 PY
pre-ART and
0.22 cases/100
PY during first
15 months
ART
–
Jones et al, 2000 United States – 1992–1998 Multicenter cohort Adult/
Adolescent Spectrum of HIV
Disease project
Steep
decreases in
TB incidence
rates
0.2 (0.1–0.5)
Girardi et al, 2000 Italy 1360 1995–1996 Multicenter cohort Not stated 0.08 (0.01–0.88)
Santoro-Lopes et al,
2002
Brazil 255 1991–1998 Prospective cohort Not stated 0.2 (0.04–1.13)
Badri et al, 2002 South Africa 1034 1992–2001 Rates compared in separate
prospective observational cohorts
receiving or not receiving ART
Markedly
lower TB rates
across a broad
spectrum of
baseline CD4
counts and
WHO stage
0.19 (0.09–0.38)
Golub et al, 2007 Brazil 11,026 2003–2005 Multicenter retrospective cohort Rates among
those
receiving and
not receiving
ART were 1.9
and 4.0 cases/
100 PY,
respectively
0.46 (0.33–0.63)
Miranda et al, 2007 Brazil 463 1995–2001 Multicenter retrospective study Rates among
those
receiving and
not receiving
ART were 1.2
and 13.4 cases/
100 PY,
respectively
0.2 (0.1–0.6)
Muga et al, 2007 Spain 2238 1980s–2004 Multicenter seroconverter cohort Marked
reduction in
rates after
1995 in all
HIV
0.31 (0.17–0.54)
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Study Setting N Study Period Study Design Impact of
ART on TB
Incidence
Rates
Adjusted
Hazards Ratio
(95%CI)
transmission
categories
Moreno et al, 2008 Spain 4268 1997–2003 Multicenter hospital-based cohort Rates among
those
receiving and
not receiving
ART were 0.5
and 1.6 cases/
100 PY,
respectively
0.26 (0.16–0.40)
Golub et al, 2009 South Africa 2778 2003–2007 Retrospective data from two study
sites
Rates among
those
receiving and
not receiving
ART were 4.6
and 7.1 cases/
100 PY,
respectively
0.36 (0.25–0.51)
Abbreviation: PY, person-years.
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Table 2
Studies (n=14) reporting tuberculosis incidence rates during antiretroviral therapy
Study Setting N Median /
Mean
Follow-up
(Months)
Median
Baseline
CD4 Cell
Count
(Cells/μL)
TB Cncidence, Cases/
100 PY (Months of
ART)
Estimated
National TB
Incidence
Rate (Per 100
Population)a
High-income countries
Girardi et al, 2005 Germany, Switzerland,
France, Netherland, UK,
Canada, United States
17,142 25.8 280 1.31 (0–3)
0.78 (4–6)
0.46 (7–12)
0.33 (13–24)
0.15 (25–36)
0.005–0.016
Brinkhof et al, 2007 Europe, North America 22,217 11.0 234 1.7 (0–3)
1.0 (4–6)
0.6 (7–12)
<0.015
Moreno et al, 2008 Spain 4268 46.0 324 0.5 0.035
Resource-limited settings
Badri et al, 2002 South Africa 1034 16.8 254 2.4 0.406
Santoro-Lopes et al,
2002
Brazil 284 22.0 – 8.4 0.071
Lawn et al. 2005 South Africa 346 40.0 242 3.35 (0–12)
1.56 (13–24)
1.36 (25–36)
0.90 (37–48)
1.01 (49–60)
0.576
Seyler et al, 2005 Côte d'Ivoire 129 26.0 125 4.8 0.368
Lawn et al, 2006 South Africa 1002 0.9 96 23.0 (0–3)10.7
(4–6)
7.0 (7–12)
3.7 (13–24)
0.898
Bonnet et al, 2006 Kenya
Malawi
Cameroon
Thailand
Cambodia
3151 3.7
6.7
11.1
3.7
7.3
– 17.6
14.3
4.8
10.4
7.6
0.419
0.416
0.194
0.142
–
Golub et al, 2007 Brazil 11,026 17.0 – 1.90 0.053
Miranda et al, 2007 Brazil 245 – – 1.2 0.064
Brinkhof et al, 2007 Botswana, Brazil, Côte
d'Ivoire, India, Kenya,
Nigeria, Malawi,
Morocco, Senegal, South
Africa, Thailand, Uganda
4540 9.6 107 10.7 (0–3)
7.5 (4–6)
5.2 (7–12)
0.055–0.852
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Study Setting N Median /
Mean
Follow-up
(Months)
Median
Baseline
CD4 Cell
Count
(Cells/μL)
TB Cncidence, Cases/
100 PY (Months of
ART)
Estimated
National TB
Incidence
Rate (Per 100
Population)a
Moore et al, 2007 Uganda 1044 17.0 127 3.9 (overall)
7.5 (0–6)
2.4 (7–12)
1.9 (13–18)
0.385
Walters et al, 2008 South Africa 290 (pediatric) – – 6.4 0.898
Abbreviation: PY, person-years.
a
National TB incidence estimates at the midpoint of the study duration; data sourced from World Health Organization. Global tuberculosis control:
epidemiology, strategy, financing. Geneva (Switzerland): World Health Organization; 2009. WHO/HTM/TB/2009.411.
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Table 3
Observational cohort studies (n=8) showing the impact of antiretroviral therapy on mortality among patients who
have HIV-associated tuberculosis
Study Country Study Design Outcome
Dheda et al, 2004 United Kingdom Retrospective study of patients who had HIV-
TB (n = 99) treated in pre-ART era and in ART
era
Adjusted hazards of death or new AIDS-defining
illness was 0.34 (95%CI, 0.18–0.63) during ART
era
Manosuthi et al, 2006 Thailand Retrospective cohort study (n = 1003)
comparing mortality in a historic natural-
history cohort with rates in an ART cohort
The adjusted hazards of death associated with use
of ART was 0.05 (95%CI, 0.02–0.12).
Akksilp et al, 2007 Thailand Prospective cohort (n = 329) comparing
patients receiving and not receiving ART
Adjusted hazards of death was 0.2 (95%CI, 0.1–
0.4)
Zachariah et al, 2007 Malawi Retrospective observational cohort in which a
proportion of patients started ART during the
continuation phase of TB treatment (n = 658)
No difference in mortality between patients who
chose or did not choose to receive ART, but
potential allocation bias according to degree of
immunodeficiency and most deaths occurred pre-
ART during intensive phase
Nahid et al, 2007 United States Retrospective observational cohort (n = 264)
1990–2001 spanning pre-ART and ART era
Use of ART protected against mortality compared
with patients who did not receive ART (hazard ratio
0.36, 95% CI 0.14–0.91)
Haar et al, 2007 Netherlands Retrospective observational study of national
data 1993–2001 spanning pre-ART and ART
era
Compared with 1993–1995, adjusted odds of death
during 1999–2001 was 0.46 (95%CI, 0.24–0.89),
whereas no such change was observed among
patients who had TB and were not infected with
HIV
Varma et al, 2009 Thailand Prospective multicenter observational study (n
= 667) comparing patients receiving and not
receiving ART
Adjusted hazards of death among those who
received ART was 0.16 (95%CI, 0.07–0.36)
Velasco et al, 2009 Spain Retrospective observational cohort 1987–
2004 (n = 313) comparing patients receiving
and not receiving ART
Compared with no ART, initiation of ART within
the first 2 months of TB treatment was associated
with an adjusted hazards of death of 0..37 (95%CI,
0.17–0.66)
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